CommentEvidence that new antihypertensives are superior to older drugs
References (18)
- et al.
Cardiovascular prevention and blood pressure reduction: a meta-analysis
Lancet
(2001) - et al.
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOTT—LLA): a multicentre randomised controlled trial
Lancet
(2003) - et al.
VALUE: analysis of results
Lancet
(2004) - et al.
Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: intervention as a goal in hypertensive treatment (INSIGHT)
Lancet
(2000) - et al.
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
Lancet
(2004) - et al.
Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials
Hypertens Res
(2005) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
JAMA
(2002)Diuretic versus α-blocker as first step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Hypertension
(2003)- et al.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
Lancet
(2005)
Cited by (63)
Association of hemoglobin levels with blood pressure and hypertension in a large population-based study: The Korea National Health and Nutrition Examination Surveys 2008-2011
2015, Clinica Chimica ActaCitation Excerpt :The higher regression coefficients for DBP than that for SBP in our study probably indicate that DBP is more related with peripheral resistance and therefore, more related to Hb concentrations [16]. The effect of Hb concentrations on BP may be very relevant for clinical practice because even a subtle difference of 1–2 mmHg was sufficient to explain the cardiovascular benefit [9,17,18]. A 2 mmHg reduction in DBP was estimated to be large enough to induce a 17% decrease in the prevalence of diastolic hypertension, a 6% reduction in coronary heart disease, and a 15% decrease in stroke and transient ischemic attacks, according to an overview of large observational studies and randomized clinical trials [19].
Use of drug combinations in the treatment of hypertension: An imperative need
2008, Medicina ClinicaManagement of Hypertension in Peripheral Arterial Disease
2008, Progress in Cardiovascular DiseasesCitation Excerpt :The recent ASCOT-BPLA trial85 confirmed that treatment with only diuretics or β-blocking agents or a combination increased the risk of new-onset DM by about 40% and had unfavorable metabolic side effects.87 The ASCOT-BPLA study strongly supports the use of newer drugs in complicated hypertension with associated risk factors and metabolic disturbances.87 Without any doubt, hypertension complicated with IC fulfills these criteria, and potentially, also a large part of hypertensive patients with a low ABI do so.
Management of High Blood Pressure
2022, Primer on Nephrology, Second EditionFundamentals of pharmacology: An applied approach for nursing and health
2015, Fundamentals of Pharmacology: An Applied Approach for Nursing and Health